Education
About Us
Working with TipRanks
Follow Us
Ardelyx Inc (DE:41X)
:41X
41X Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.15 - €8.57
Previous CloseN/A
Volume0.00
Average Volume (3M)496.00
Market Cap
€1.23B
Enterprise Value€1.54B
Total Cash (Recent Filing)$36.15M
Total Debt (Recent Filing)$104.93M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding238,356,220
10 Day Avg. Volume356
30 Day Avg. Volume496
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.74
Price to Cash Flow (P/CF)31.80
P/FCF Ratio31.80
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.44
Enterprise Value/Ebitda-92.12
Forecast
1Y Price Target
€10.03Price Target Upside106.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Financial Performance4Q24 was ARDX's first product-driven profitable quarter, and minimal cash impact from operations is expected through FY25.
Market OpportunitiesIbsrela and Xphozah continue to build momentum in large market opportunities with no second-line competition, supporting a clear path to returned profitability.
Bears Say
Regulatory ChallengesThe District Court's dismissal of Ardelyx's lawsuit allows the CMS to include XPHOZAH in the ESRD PPS bundle, which negatively impacts the company's stock.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.69% Insiders
20.18% Mutual Funds
10.93% Other Institutional Investors
53.09% Public Companies and Individual Investors
41X FAQ
What was Ardelyx Inc’s price range in the past 12 months?
Ardelyx Inc lowest stock price was €4.15 and its highest was €8.57 in the past 12 months.
What is Ardelyx Inc’s market cap?
Ardelyx Inc’s market cap is €1.23B.
When is Ardelyx Inc’s upcoming earnings report date?
Ardelyx Inc’s upcoming earnings report date is May 01, 2025 which is in 50 days.
How were Ardelyx Inc’s earnings last quarter?
Ardelyx Inc released its earnings results on Feb 20, 2025. The company reported €0.018 earnings per share for the quarter, beating the consensus estimate of €0.004 by €0.015.
Is Ardelyx Inc overvalued?
According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued.
Does Ardelyx Inc pay dividends?
Ardelyx Inc does not currently pay dividends.
What is Ardelyx Inc’s EPS estimate?
Ardelyx Inc’s EPS estimate is -0.1.
How many shares outstanding does Ardelyx Inc have?
Ardelyx Inc has 238,356,220 shares outstanding.
What happened to Ardelyx Inc’s price movement after its last earnings report?
Ardelyx Inc reported an EPS of €0.018 in its last earnings report, beating expectations of €0.004. Following the earnings report the stock price went down -14.624%.
Which hedge fund is a major shareholder of Ardelyx Inc?
Currently, no hedge funds are holding shares in DE:41X
---
Ardelyx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.03 (106.40% Upside)
€10.03 (106.40% Upside)
Blogger Sentiment
Bullish
DE:41X Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.80%
12-Months-Change
Fundamentals
Return on Equity
-23.01%
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
Ardelyx Inc
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
41X Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.Read More>---
41X Stock 12 Month Forecast
Average Price Target
€10.03
▲(106.40% Upside)
Technical Analysis
Best Analysts Covering 41X
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+59.17%
reiterated a buy rating 4 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +59.17% per trade.
---